Diabetic Siltussin DAS-Na

Product NDC
54838-138
11-digit product format
548380138
Labeler code
54838
Product ID
54838-138_e9401155-c63d-44e5-a1a3-41619110a228
Type
HUMAN OTC DRUG
Nonproprietary name
Guaifenesin
Dosage form
LIQUID
Route
ORAL
Labeler
Lannett Company, Inc.
Application
part341
Marketing category
OTC MONOGRAPH FINAL
Marketing start
2005-12-05
Marketing end
0000-00-00
Substance
GUAIFENESIN
Active strength
100 mg/5mL
NDC exclude flag
No
Listing certified through
2020-12-31
Current FDA listing
Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 2 matching rows.

Dataset, Scope, Product NDC table
DatasetScopeProduct NDCPackage NDCCodeStatusReporting periodSource date
excluded productproduct54838-138DDiscontinued by firm2026-10-05
excluded packagepackage54838-13854838-138-40DDiscontinued by firm2026-10-05

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 24 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source dateDatasetScopePackage NDCSnapshotSource SHA-256
2025-12-14 17:58 UTC · source 2025-12-05excluded productproductd630ba8d3edf…732f749b63fb…
2025-12-14 17:58 UTC · source 2025-12-05excluded packagepackage54838-138-40d630ba8d3edf…732f749b63fb…
2025-08-27 00:01 UTC · source 2025-08-26excluded productproductf5e01cc5f278…a2eaf40c39c3…
2025-08-27 00:01 UTC · source 2025-08-26excluded packagepackage54838-138-40f5e01cc5f278…a2eaf40c39c3…
2025-04-01 02:39 UTC · source 2025-03-31excluded productproduct2ef7874e63bc…57b86245f4fa…
2025-04-01 02:39 UTC · source 2025-03-31excluded packagepackage54838-138-402ef7874e63bc…57b86245f4fa…
2025-03-28 20:22 UTC · source 2025-03-28excluded productproducta1b67e2a42f9…c4cf2c586c0d…
2025-03-28 20:22 UTC · source 2025-03-28excluded packagepackage54838-138-40a1b67e2a42f9…c4cf2c586c0d…
2025-03-22 03:12 UTC · source 2025-03-21excluded productproductcfe11265f3b6…090c488252e2…
2025-03-22 03:12 UTC · source 2025-03-21excluded packagepackage54838-138-40cfe11265f3b6…090c488252e2…
2025-03-10 12:48 UTC · source 2025-03-10excluded productproductcdf11ea48f46…ba0047e9e063…
2025-03-10 12:48 UTC · source 2025-03-10excluded packagepackage54838-138-40cdf11ea48f46…ba0047e9e063…
2025-02-02 03:52 UTC · source 2025-01-31excluded productproduct302b2466d912…e7b80fea0513…
2025-02-02 03:52 UTC · source 2025-01-31excluded packagepackage54838-138-40302b2466d912…e7b80fea0513…
2025-01-20 13:05 UTC · source 2025-01-20excluded productproducted331223b511…672a5bd82f5f…
2025-01-20 13:05 UTC · source 2025-01-20excluded packagepackage54838-138-40ed331223b511…672a5bd82f5f…
2025-01-11 03:41 UTC · source 2025-01-10excluded productproduct0efc9e666f02…f202fb6c5f17…
2025-01-11 03:41 UTC · source 2025-01-10excluded packagepackage54838-138-400efc9e666f02…f202fb6c5f17…
2024-11-09 02:27 UTC · source 2024-11-08excluded productproductad56d346431e…cc804d4bbf1e…
2024-11-09 02:27 UTC · source 2024-11-08excluded packagepackage54838-138-40ad56d346431e…cc804d4bbf1e…
2024-10-04 04:10 UTC · source 2024-10-03excluded productproduct367a005e9d99…383a685ebd0f…
2024-10-04 04:10 UTC · source 2024-10-03excluded packagepackage54838-138-40367a005e9d99…383a685ebd0f…
2024-07-10 04:00 UTC · source 2024-07-09excluded productproduct557ba5c1ecfa…9c80585c8c6e…
2024-07-10 04:00 UTC · source 2024-07-09excluded packagepackage54838-138-40557ba5c1ecfa…9c80585c8c6e…

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
54838-138-40ML - Milliliter54838-13831465a19-5e44-476c-9520-5e665f998d4f12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIIDailyMed labelSPL versionUploaded
GuaifenesinACTIVE INGREDIENT495W7451VQDIABETIC SILTUSSIN DAS-NA (GUAIFENESIN) LIQUID [SILARX PHARMACEUTICALS, INC]12
GuaifenesinACTIVE MOIETY495W7451VQDIABETIC SILTUSSIN DAS-NA (GUAIFENESIN) LIQUID [SILARX PHARMACEUTICALS, INC]12
acesulfame potassiumINACTIVE INGREDIENT23OV73Q5G9DIABETIC SILTUSSIN DAS-NA (GUAIFENESIN) LIQUID [SILARX PHARMACEUTICALS, INC]12
anhydrous citric acidINACTIVE INGREDIENTXF417D3PSLDIABETIC SILTUSSIN DAS-NA (GUAIFENESIN) LIQUID [SILARX PHARMACEUTICALS, INC]12
aspartameINACTIVE INGREDIENTZ0H242BBR1DIABETIC SILTUSSIN DAS-NA (GUAIFENESIN) LIQUID [SILARX PHARMACEUTICALS, INC]12
benzoic acidINACTIVE INGREDIENT8SKN0B0MIMDIABETIC SILTUSSIN DAS-NA (GUAIFENESIN) LIQUID [SILARX PHARMACEUTICALS, INC]12
HYPROMELLOSE 2910 (4000 MPA.S)INACTIVE INGREDIENTRN3152OP35DIABETIC SILTUSSIN DAS-NA (GUAIFENESIN) LIQUID [SILARX PHARMACEUTICALS, INC]12
methylparabenINACTIVE INGREDIENTA2I8C7HI9TDIABETIC SILTUSSIN DAS-NA (GUAIFENESIN) LIQUID [SILARX PHARMACEUTICALS, INC]12
propylene glycolINACTIVE INGREDIENT6DC9Q167V3DIABETIC SILTUSSIN DAS-NA (GUAIFENESIN) LIQUID [SILARX PHARMACEUTICALS, INC]12
waterINACTIVE INGREDIENT059QF0KO0RDIABETIC SILTUSSIN DAS-NA (GUAIFENESIN) LIQUID [SILARX PHARMACEUTICALS, INC]12
GuaifenesinACTIVE INGREDIENT495W7451VQDIABETIC SILTUSSIN DAS-NA (GUAIFENESIN) LIQUID [PREFERRED PHARMACEUTICALS INC.]2
GuaifenesinACTIVE MOIETY495W7451VQDIABETIC SILTUSSIN DAS-NA (GUAIFENESIN) LIQUID [PREFERRED PHARMACEUTICALS INC.]2
acesulfame potassiumINACTIVE INGREDIENT23OV73Q5G9DIABETIC SILTUSSIN DAS-NA (GUAIFENESIN) LIQUID [PREFERRED PHARMACEUTICALS INC.]2
anhydrous citric acidINACTIVE INGREDIENTXF417D3PSLDIABETIC SILTUSSIN DAS-NA (GUAIFENESIN) LIQUID [PREFERRED PHARMACEUTICALS INC.]2
aspartameINACTIVE INGREDIENTZ0H242BBR1DIABETIC SILTUSSIN DAS-NA (GUAIFENESIN) LIQUID [PREFERRED PHARMACEUTICALS INC.]2
benzoic acidINACTIVE INGREDIENT8SKN0B0MIMDIABETIC SILTUSSIN DAS-NA (GUAIFENESIN) LIQUID [PREFERRED PHARMACEUTICALS INC.]2
HYPROMELLOSE 2910 (4000 MPA.S)INACTIVE INGREDIENTRN3152OP35DIABETIC SILTUSSIN DAS-NA (GUAIFENESIN) LIQUID [PREFERRED PHARMACEUTICALS INC.]2
methylparabenINACTIVE INGREDIENTA2I8C7HI9TDIABETIC SILTUSSIN DAS-NA (GUAIFENESIN) LIQUID [PREFERRED PHARMACEUTICALS INC.]2
propylene glycolINACTIVE INGREDIENT6DC9Q167V3DIABETIC SILTUSSIN DAS-NA (GUAIFENESIN) LIQUID [PREFERRED PHARMACEUTICALS INC.]2
waterINACTIVE INGREDIENT059QF0KO0RDIABETIC SILTUSSIN DAS-NA (GUAIFENESIN) LIQUID [PREFERRED PHARMACEUTICALS INC.]2

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionUnitsMarketing startMarketing endSampleExclude flagStatus
54838-138-4054838013840118 mL in 1 BOTTLE, PLASTIC (54838-138-40) 118 ml2005-12-050000-00-00NoNoCurrent